Ruboxistaurin mesilate hydrate for diabetic retinopathy

Drugs of Today

Volumn 45, Issue 4, 2009, Pages 269-274

  Schwartz, Stephen G ^a   Flynn Jr , Harry W ^a   Aiello, Lloyd Paul ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTEIN KINASE C BETA; RUBOXISTAURIN;

ABDOMINAL PAIN; BLINDNESS; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; PATHOGENESIS; RETINA BLOOD FLOW; REVIEW; SIDE EFFECT;

ANIMALS; DIABETIC RETINOPATHY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; INDOLES; MALEIMIDES; PROTEIN KINASE C; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68249094043     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.045.004.1354195     Document Type: Review

References (51)

1. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004, 122(4): 477-485
2. Rein, D.B., Zhang, P., Wirth, K.E. et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006, 124(12): 1754-1760 (Pubitemid 44920172)
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14): 977-986
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131): 837-853
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol 1985, 103(12): 1796-1806
6. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88(7): 583-600.
7. Schwartz, S.G., Flynn Jr., H.W. Pharmacotherapies for diabetic retinopathy: Present and future. Exp Diabetes Res 2007, 2007: article ID 52487.
8. Martidis, A., Duker, J.S., Greenberg, P.B., Rogers, A.H., Puliafito, C.A., Reichel, E., Baumal, C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109(5): 920-927 (Pubitemid 34465226)
9. Kuppermann, B.D., Blumenkranz, M.S., Haller, J.A. et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007, 125(3): 309-317 (Pubitemid 46425557)
10. Kuppermann, B.D, Thomas, E.L., de Smet, M.D., Grillone, L.R.; Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am J Ophthalmol 2005, 140(4): 573-584
11. Cunningham Jr., E.T., Adamis, A.P., Altaweel, M. et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112(10): 1747-1757
12. Spaide, R.F., Fisher, Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006, 26(3): 275-278 (Pubitemid 44318179)
13. Chun, D.W., Heier, J.S., Topping, T.M., Duker, J.S., Bankert, J.M. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006, 113(10): 1706-1712
14. Lang, G.E. Pharmacological treatment of diabetic retinopathy. Ophthalmologic 2007, 221(2): 112-117 (Pubitemid 46465436)
15. Aiello, L.P. The potential role of PKC β in diabetic retinopathy and macular edema. Surv Ophthalmol 2002, 47(Suppl. 2): S263-9.
16. Donnelly, R., Idris, I., Forrester, J.V. Protein kinase C inhibition and diabetic retinopathy: A shot in the dark at translational research. Br J Ophthalmol 2004, 88(1): 145-151 (Pubitemid 38091382)
17. Mellor, H., Parker, P.J. The extended protein kinase C superfamily. Biochem J 1998, 332(Pt. 2):281-292. (Pubitemid 28271856)
18. Clarke, M., Dodson, P.M. PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab 2007, 21(4): 573-586 (Pubitemid 350177570)
19. Bullock W.H., Magnuson, S.R., Choi, S., Gunn, D.E., Rudolph, J. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem 2002, 2(9): 915-938
20. Sheetz, M.J., King, G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002, 288(20): 2579-2588
21. Ceolotto, G., Gallo, A., Miola, M. et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 1999, 48(6): 1316-1322 (Pubitemid 29241032)
22. Huang, Q., Yuan, Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997, 273(5, Pt. 2): H2442-51. (Pubitemid 27508324)
23. Li, P.F., Maasch, C., Haller, H., Dietz, R., von Harsdorf, R. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 1999, 100(9): 967-973 (Pubitemid 29407178)
24. Pomero, F., Allione, A., Betramo, E. et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003, 46(3): 416-419 (Pubitemid 36547598)
25. Williams, B., Gallacher, B., Patel, H., Orme, C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997, 46(9): 1497-1503 (Pubitemid 27369089)
26. Park, J.Y., Takahara, N., Gabriele, A. et al. Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation. Diabetes 2000, 49(7): 1239-1248 (Pubitemid 30439101)
27. Park, C.W., Kim, J.H., Lee, J.H. et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000, 43(12): 1544-1553
28. Craven, P.A., Studer, R.K., Negrete, H., DeRubertis, F.R. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995, 9(4): 241-245
29. Jirousek, M.R., Gillig, J.R., Gonzalez, C.M. et al. (S)-13- [(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16 21-dimetheno-1H,13H- diebenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996, 39(14): 2664-2671
30. [No authors listed]. Ruboxistaurin: LY 333531. Drugs R D 2007, 8(3): 193-199
31. Engel, G.L., Farid, N.A., Faul, M.M., Richardson, L.A., Winneroski, L.L. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000, 198(2), 239-247
32. Suzuma, K., Takahara, N., Suzuma, I. et al. Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002, 99(2): 721-726 (Pubitemid 34106577)
33. Xia, P., Aiello, L.P., Ishii, H. et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996, 98(9): 2018-2026 (Pubitemid 26376289)
34. Ishii, H., Jirousek, M.R., Koya, D. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β-inhibitor. Science 1996, 272(5262): 728-731 (Pubitemid 26000279)
35. Aiello, L.P., Bursell, S.E., Clermont, A. et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997, 46(9): 1473-1480 (Pubitemid 27369086)
36. Nonaka, A., Kiryu, J., Tsujikawa, A. et al. PKC-β inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000, 41(9): 2702-2706 (Pubitemid 30624402)
37. Xu, X., Zhu, Q., Xia, X., Zhang, S., Gu, Q., Luo, D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozocin-induced diabetic rats. Curr Eye Res 2004, 28(4): 251-256 (Pubitemid 38491318)
38. Danis, R.P., Bingaman, D.P., Jirousek, M., Yang, Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci 1998, 39(1): 171-179 (Pubitemid 28040476)
39. Burkey, J.L., Campanale, K.M., Barbuch, R., O'Bannon, D., Rash, J., Benson, C., Small, D. Disposition of [14C] ruboxistaurin in humans. Drug Metab Dispos 2006, 34(11): 1909-17.
40. Wise, S., Yuen, E., Chan, C., Poo, Y.K., Teng, L., Lau, T., Voelker, J. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522. Clin Pharmacokinet 2006, 45(3): 297-303. (Pubitemid 43327494)
41. Beckman, J.A., Goldfine, A.B., Gordon, M.B., Garrett, L.A., Creager, M.A. Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002, 90(1): 107-111
42. McGill, J.B., King, G.L., Berg, P.H., Price, K.L., Kles, K. A., Bastyr, E.J., Hyslop, D.L. Clinical safety of the selective PKC-β inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006, 5(6): 835-845
43. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005, 54(7): 2188-2197
44. PKC-DRS2 Group, Aiello, L.P., Davis, M.D. et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113(12): 2221-2230
45. The PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007, 125(3): 318-324
46. Strøm, C., Sander, B., Klemp, K., Aiello, L.P., Lund-Anderson, H., Larsen, M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 2005, 46(10): 3855-3858 (Pubitemid 44264697)
47. Sander, B., Thornit, D.N., Colmorn, L. et al Progression of diabetic macular edema: Correlation with blood-retinal barrier permeability, retinal thickness, and retinal vascular diameter. Invest Ophthalmol Vis Sci 2007, 48(9): 3983-3987 (Pubitemid 351261018)
48. Aiello, L.P., Clermont, A., Arora, V., Davis, M.D., Sheetz, M.J., Bursell, S.E. Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006, 47(1): 86-92. (Pubitemid 46780799)
49. Sheetz, M.J., Aiello, L.P., Shahri, N. et al. Longer treatment duration with ruboxistaurin (RBX) is associated with less visual acuity decline over a 6-year period despite cessation and reinstitution of therapy - Results of an open-label extension of the Protein Kinase C-Diabetic Retinopathy Study 2 (PKC-DRS2). Invest Ophthalmol Vis Sci 2009, 50: E-Abstract 4330.
50. Hee, M.R., Puliafito, C.A., Wong, C. et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995, 113(8): 1019-1029
51. Glassman, A.R., Beck, R.W., Browning, D.J., Danis, R.P., Kollman, C.; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of optical coherence tomography retinal thickness measurements in diabetic macular edema with and without reading center manual grading from a clinical trials perspective. Invest Ophthalmol Vis Sci 2008, 50(2): 560-566